In patients with BTK-pretreated chronic lymphocytic leukemia (CLL), AbbVie and Roche’s Venclexta (venetoclax) is the drug to beat. But no companies had taken a daunting head-to-head challenge—until ...
Linda Hoffman-Pugh, a former housekeeper for JonBenét Ramsey's family, has died at the age of 82. Hoffman-Pugh was working for the family when JonBenét was tragically murdered at just 6 years old on ...
Patsy Kensit will return to Emmerdale after two decades to reprise her role as Sadie King. The actress played the villainous character on the ITV soap for a two-year stint between 2004 and 2006. She ...
Emmerdale has confirmed the return of Patsy Kensit as Sadie King. It was recently reported that the star, who appeared on EastEnders a few years ago, would be back as the villainous character after 20 ...
You don’t mess with the classics. In a chaotic world that ceaselessly hurls distractions at us through the digital rectangular devices in our pockets, it’s often the slow, frill-less, anachronistic ...
“These results highlight zanubrutinib monotherapy as an effective treatment option for all patients with treatment-naive CLL/[small lymphocytic leukemia], including patients who might otherwise be ...
In "Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels continue their conversation on communicating ...
Eli Lilly has chalked up another victory in the chronic lymphocytic leukemia (CLL) space, as its BTK inhibitor Jaypirca delivered its fourth positive phase 3 readout in the blood cancer. Monday, Lilly ...
Please provide your email address to receive an email when new articles are posted on . The combination is the first all-oral, fixed duration treatment for patients with CLL and or small lymphocytic ...
Retreatment with venetoclax and rituximab in CLL patients achieved 100% response rates and prolonged progression-free survival. Median progression-free survival was 9.5 years from initial treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results